Cargando…

COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus

COVID-19 vaccination has been shown to be safe in patients with systemic lupus erythematosus (SLE), but data on vaccine-associated adverse events (AEs) during the antenatal and lactation period are scarce or lacking. We investigated COVID-19 vaccination-related AEs in pregnant SLE patients from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannopoulou, Nefeli, Gupta, Latika, Andreoli, Laura, Lini, Daniele, Nikiphorou, Elena, Aggarwal, Rohit, Agarwal, Vikas, Parodis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896878/
https://www.ncbi.nlm.nih.gov/pubmed/36740090
http://dx.doi.org/10.1016/j.autrev.2023.103292
_version_ 1784882140132933632
author Giannopoulou, Nefeli
Gupta, Latika
Andreoli, Laura
Lini, Daniele
Nikiphorou, Elena
Aggarwal, Rohit
Agarwal, Vikas
Parodis, Ioannis
author_facet Giannopoulou, Nefeli
Gupta, Latika
Andreoli, Laura
Lini, Daniele
Nikiphorou, Elena
Aggarwal, Rohit
Agarwal, Vikas
Parodis, Ioannis
author_sort Giannopoulou, Nefeli
collection PubMed
description COVID-19 vaccination has been shown to be safe in patients with systemic lupus erythematosus (SLE), but data on vaccine-associated adverse events (AEs) during the antenatal and lactation period are scarce or lacking. We investigated COVID-19 vaccination-related AEs in pregnant SLE patients from the COVAD study, a global esurvey involving 157 collaborators from 106 countries. A total of 9201 complete responses were extracted. Among 6787 (73.8%) women, we identified 70 (1.1%) who were exposed to at least one COVID-19 vaccine dose during pregnancy, 11 with SLE. Delayed onset (>7 days) vaccine-related AEs were triangulated with disease activity, treatment changes due to flare after vaccination, and COVID-19 infections in vaccinated pregnant women. Health-related quality of life and physical function was recorded using PROMIS. Age of patients ranged from 28 to 39 years; 5/11 women were of Asian origin. None of these patients reported major vaccine AEs or change in the status of their autoimmune disease. Although minor AEs were common, they did not impair daily functioning, and the symptoms resolved after a median of 3 (IQR: 2.5–5.0) days. All patients reported good to excellent health status. No adverse pregnancy outcomes were reported. Importantly, none of the patients reported thrombotic events post-vaccination, which provides reassurance in a patient population with a high risk for cardiovascular comorbidity and thrombosis, especially in the presence of antiphospholipid antibodies or the antiphospholipid syndrome, a considerable portion of SLE patients. Our findings provide reassurance and can contribute to informed decisions regarding vaccination in patients with SLE and high-risk pregnancies due to their background autoimmune disease. The risk/benefit ratio of COVID-19 vaccination appears favourable, with vaccines both providing passive immunisation to the fetus and active immunisation to the mother with no signals of exacerbation of the mother's autoimmune disease.
format Online
Article
Text
id pubmed-9896878
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-98968782023-02-06 COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus Giannopoulou, Nefeli Gupta, Latika Andreoli, Laura Lini, Daniele Nikiphorou, Elena Aggarwal, Rohit Agarwal, Vikas Parodis, Ioannis Autoimmun Rev Article COVID-19 vaccination has been shown to be safe in patients with systemic lupus erythematosus (SLE), but data on vaccine-associated adverse events (AEs) during the antenatal and lactation period are scarce or lacking. We investigated COVID-19 vaccination-related AEs in pregnant SLE patients from the COVAD study, a global esurvey involving 157 collaborators from 106 countries. A total of 9201 complete responses were extracted. Among 6787 (73.8%) women, we identified 70 (1.1%) who were exposed to at least one COVID-19 vaccine dose during pregnancy, 11 with SLE. Delayed onset (>7 days) vaccine-related AEs were triangulated with disease activity, treatment changes due to flare after vaccination, and COVID-19 infections in vaccinated pregnant women. Health-related quality of life and physical function was recorded using PROMIS. Age of patients ranged from 28 to 39 years; 5/11 women were of Asian origin. None of these patients reported major vaccine AEs or change in the status of their autoimmune disease. Although minor AEs were common, they did not impair daily functioning, and the symptoms resolved after a median of 3 (IQR: 2.5–5.0) days. All patients reported good to excellent health status. No adverse pregnancy outcomes were reported. Importantly, none of the patients reported thrombotic events post-vaccination, which provides reassurance in a patient population with a high risk for cardiovascular comorbidity and thrombosis, especially in the presence of antiphospholipid antibodies or the antiphospholipid syndrome, a considerable portion of SLE patients. Our findings provide reassurance and can contribute to informed decisions regarding vaccination in patients with SLE and high-risk pregnancies due to their background autoimmune disease. The risk/benefit ratio of COVID-19 vaccination appears favourable, with vaccines both providing passive immunisation to the fetus and active immunisation to the mother with no signals of exacerbation of the mother's autoimmune disease. Elsevier B.V. 2023-04 2023-02-03 /pmc/articles/PMC9896878/ /pubmed/36740090 http://dx.doi.org/10.1016/j.autrev.2023.103292 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Giannopoulou, Nefeli
Gupta, Latika
Andreoli, Laura
Lini, Daniele
Nikiphorou, Elena
Aggarwal, Rohit
Agarwal, Vikas
Parodis, Ioannis
COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
title COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
title_full COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
title_fullStr COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
title_full_unstemmed COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
title_short COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
title_sort covid-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896878/
https://www.ncbi.nlm.nih.gov/pubmed/36740090
http://dx.doi.org/10.1016/j.autrev.2023.103292
work_keys_str_mv AT giannopoulounefeli covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT guptalatika covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT andreolilaura covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT linidaniele covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT nikiphorouelena covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT aggarwalrohit covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT agarwalvikas covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus
AT parodisioannis covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus